Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent

Development of an Aryloxazole Derivative as a Brain-Permeable Anti-Glioblastoma Agent

Glioblastoma drug development has been difficult due to the extremely low blood brain barrier (BBB) penetration of conventional anti-cancer agents. P-glycoprotein, an efflux membrane transporter, is responsible for the poor brain uptake of small and hydrophobic drug substances. To develop brain-pene...

Full description

Bibliographic Details
Main Authors: Seulgi Shin, Sungsu Lim, Ji Yeon Song, Dohee Kim, Min Jeong Choi, Changdev G. Gadhe, A Young Park, Ae Nim Pae, Yun Kyung Kim
Format: Article
Language:English
Published: MDPI AG 2019-09-01
Series:Pharmaceutics
Subjects:
aryloxazole derivative
p-glycoprotein inhibition
anti-glioblastoma agent
Online Access:https://www.mdpi.com/1999-4923/11/10/497

Internet

https://www.mdpi.com/1999-4923/11/10/497

Similar Items